Science Corporation raises $160M for biohybrid visual cortex implant backed by ARCH Venture Partners
Summary
Science Corporation raised $160M in a round led by ARCH Venture Partners, with participation from Founders Fund and Sequoia Capital, to develop their biohybrid visual cortex implant that integrates living neurons with electronics to restore sight. Unlike conventional electrode-based visual prostheses, Science Corp's approach bonds biological neural tissue to silicon, aiming for higher resolution and better long-term biocompatibility than metal electrodes alone.
Why it matters
ARCH Venture Partners led this round — the same firm that backed Synchron, Alnylam, and other landmark life science companies. Their $160M conviction bet on biohybrid neural interfaces signals that the field has moved beyond proof-of-concept. Science Corp is the most technically radical BCI company with institutional backing of this scale.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial